Andersen-Tawil syndrome pathophysiology: Difference between revisions

Jump to navigation Jump to search
 
(29 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Andersen-Tawil syndrome}}
{{Andersen-Tawil syndrome}}
{{CMG}}; {{AE}} {{CP}}; {{RT}}
{{CMG}}; {{AE}} {{VKG}}


==Pathophysiology==
== Overview ==
Andersen-Tawil syndrome affects the [[heart]], symptoms are a disruption in the rhythm of the heart's lower chambers (ventricular arrhythmia) in addition to the symptoms of long QT syndrome. There are also physical abnormalities associated with Andersen-Tawil syndrome, these typically affect the head, face, and limbs. These features often include an unusually small lower jaw ([[micrognathia]]), low-set ears, and an abnormal curvature of the fingers called [[clinodactyly]].
It is understood that [[Andersen-Tawil syndrome]] is the result of [[mutation]] in ''[[KCNJ2]]'' [[gene]] which encodes for [[Kir2.1]] inward rectifier [[potassium]] channel that involves in [[cardiac]] [[repolarization]] phase. The movement of [[potassium]] [[Ion|ions]] through these [[Ion channel|channels]] is critical for maintaining the normal functions of [[skeletal muscles]] which are used for movement and [[cardiac muscle]]. [[Andersen-Tawil syndrome]] is a rare syndrome transmitted in [[autosomal dominant]] pattern.


===Genetics===
== Pathophysiology ==
The protein made by the ''KCNJ2'' gene forms a [[potassium channel|channel]] that transports potassium ions into [[muscle]] [[cell (biology)|cell]]s. The movement of potassium ions through these channels is critical for maintaining the normal functions of skeletal muscles which are used for movement and cardiac muscle. [[Mutation]]s in the ''KCNJ2'' gene alter the usual structure and function of potassium channels or prevent the channels from being inserted correctly into the cell membrane. Many mutations prevent a molecule called PIP2 from binding to the channels and effectively regulating their activity. These changes disrupt the flow of potassium ions in skeletal and cardiac muscle, leading to the periodic paralysis and irregular heart rhythm characteristic of Andersen-Tawil syndrome.<ref name="pmid22806368">{{cite journal |author=Tan SV, Z'graggen WJ, Boërio D, ''et al.'' |title=Membrane dysfunction in Andersen-Tawil syndrome assessed by velocity recovery cycles |journal=Muscle Nerve |volume=46 |issue=2 |pages=193–203 |year=2012 |month=August |pmid=22806368 |doi=10.1002/mus.23293 |url=}}</ref>


Researchers have not yet determined the role of the KCNJ2 gene in bone development, and it is not known how mutations in the gene lead to the developmental abnormalities often found in Andersen-Tawil syndrome.
=== Pathogenesis ===
 
== Overview ==


== Pathophysiology ==
* It is understood that [[Andersen-Tawil syndrome]] is the result of [[mutation]] in ''[[KCNJ2]]'' [[gene]].<ref name="pmid23644778">{{cite journal| author=Limberg MM, Zumhagen S, Netter MF, Coffey AJ, Grace A, Rogers J et al.| title=Non dominant-negative KCNJ2 gene mutations leading to Andersen-Tawil syndrome with an isolated cardiac phenotype. | journal=Basic Res Cardiol | year= 2013 | volume= 108 | issue= 3 | pages= 353 | pmid=23644778 | doi=10.1007/s00395-013-0353-1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23644778  }}</ref><ref name="pmid21493816">{{cite journal| author=Doi T, Makiyama T, Morimoto T, Haruna Y, Tsuji K, Ohno S et al.| title=A novel KCNJ2 nonsense mutation, S369X, impedes trafficking and causes a limited form of Andersen-Tawil syndrome. | journal=Circ Cardiovasc Genet | year= 2011 | volume= 4 | issue= 3 | pages= 253-60 | pmid=21493816 | doi=10.1161/CIRCGENETICS.110.958157 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21493816  }}</ref><ref name="pmid22806368">{{cite journal |author=Tan SV, Z'graggen WJ, Boërio D, ''et al.'' |title=Membrane dysfunction in Andersen-Tawil syndrome assessed by velocity recovery cycles |journal=Muscle Nerve |volume=46 |issue=2 |pages=193–203 |year=2012 |month=August |pmid=22806368 |doi=10.1002/mus.23293 |url=}}</ref>
*''[[KCNJ2]]'' [[gene]] encodes for [[Kir2.1]] inward rectifier [[potassium]] channel which is a component of the inward [[rectifier]] IK1 and involves in repolarizing current during the late phase of [[repolarization]] and plays an important role in controlling the [[diastolic]] [[membrane potential]] of the [[cardiac]] [[membrane]].<ref name="pmid20306271">{{cite journal| author=Tristani-Firouzi M, Etheridge SP| title=Kir 2.1 channelopathies: the Andersen-Tawil syndrome. | journal=Pflugers Arch | year= 2010 | volume= 460 | issue= 2 | pages= 289-94 | pmid=20306271 | doi=10.1007/s00424-010-0820-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20306271  }}</ref><ref name="pmid11371347">{{cite journal| author=Plaster NM, Tawil R, Tristani-Firouzi M, Canún S, Bendahhou S, Tsunoda A | display-authors=etal| title=Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. | journal=Cell | year= 2001 | volume= 105 | issue= 4 | pages= 511-9 | pmid=11371347 | doi=10.1016/s0092-8674(01)00342-7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11371347  }}</ref>
*The [[protein]] encoded by the ''[[KCNJ2]]'' [[gene]] which is  [[Kir2.1]] inward [[rectifier]] [[potassium]] channel transports [[potassium]] [[Ion|ions]] into [[muscle]] [[cell (biology)|cell]]s.
*The movement of [[Kir2.1]] inward [[rectifier]] [[potassium]] [[Ion channel|channel]] ions is very crucial in maintaining the normal functions of [[skeletal muscles]] which are used for movement and [[cardiac muscle]].
*Any change in the [[Kir2.1]] inward [[rectifier]] [[potassium]] [[Ion channel|channel]] ions transport especially in the heart leads to abnormal [[heart rhythm]] which will result in [[arrhythmia]] and [[Long QT syndrome|long QT]] or QU syndrome.<ref name="pmid17221872">{{cite journal| author=Haruna Y, Kobori A, Makiyama T, Yoshida H, Akao M, Doi T et al.| title=Genotype-phenotype correlations of KCNJ2 mutations in Japanese patients with Andersen-Tawil syndrome. | journal=Hum Mutat | year= 2007 | volume= 28 | issue= 2 | pages= 208 | pmid=17221872 | doi=10.1002/humu.9483 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17221872  }}</ref>
*Any change in the [[Kir2.1]] inward [[rectifier]] [[potassium]] channel ions transport in [[Skeletal muscle|skeletal muscles]] leads to [[periodic paralysis]] and and developmental abnormalities.<ref name="pmid16541386">{{cite journal| author=Ballester LY, Benson DW, Wong B, Law IH, Mathews KD, Vanoye CG et al.| title=Trafficking-competent and trafficking-defective KCNJ2 mutations in Andersen syndrome. | journal=Hum Mutat | year= 2006 | volume= 27 | issue= 4 | pages= 388 | pmid=16541386 | doi=10.1002/humu.9418 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16541386  }}</ref>


=== Physiology ===
== Genetics ==
The normal physiology of [name of process] can be understood as follows:


=== Pathogenesis ===
*[[Andersen-Tawil syndrome]] is transmitted in [[autosomal dominant]] pattern.


* The exact pathogenesis of [disease name] is not completely understood.
*[[Genes]] involved in the [[pathogenesis]] of [[Andersen-Tawil syndrome]] include:<ref>{{cite journal|author=Tristani-Firouzi M, Jensen JL, Donaldson MR, ''et al'' |title=Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome) |journal=J. Clin. Invest. |volume=110 |issue=3 |pages=381-8 |year=2002 |pmid=12163457 |doi=}}</ref><ref>{{cite journal |author=Pegan S, Arrabit C, Slesinger PA, Choe S |title=Andersen's syndrome mutation effects on the structure and assembly of the cytoplasmic domains of Kir2.1|journal=Biochemistry|volume=45 |issue=28 |pages=8599-606 |year=2006 |pmid=16834334 |doi=10.1021/bi060653d}}</ref><ref name="pmid17395133">{{cite journal| author=Sansone V, Tawil R| title=Management and treatment of Andersen-Tawil syndrome (ATS). | journal=Neurotherapeutics | year= 2007 | volume= 4 | issue= 2 | pages= 233-7 | pmid=17395133 | doi=10.1016/j.nurt.2007.01.005 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17395133  }}</ref><ref name="pmid243830702">{{cite journal| author=Nguyen HL, Pieper GH, Wilders R| title=Andersen-Tawil syndrome: clinical and molecular aspects. | journal=Int J Cardiol | year= 2013 | volume= 170 | issue= 1 | pages= 1-16 | pmid=24383070 | doi=10.1016/j.ijcard.2013.10.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24383070  }}</ref>
**''[[KCNJ2]]'' gene in 60% of the cases [[Andersen-Tawil syndrome]] (ATS) 1 type
**Unknown [[gene]] defect in 40% of the cases of [[Andersen-Tawil syndrome]] (ATS) 2 type
**''[[KCNJ5]]'' gene is also implicated but no cases reported in [[Andersen-Tawil syndrome|Andersen-Tawil syndrom]]<nowiki/>e


OR
== Associated Conditions ==
Conditions associated with [[Andersen-Tawil syndrome]] include:<ref name="AndersenKrasilnikoff1971">{{cite journal|last1=Andersen|first1=Ellen Damgaard|last2=Krasilnikoff|first2=Peter A.|last3=Overvad|first3=Hans|title=INTERMITTENT MUSCULAR WEAKNESS, EXTRASYSTOLES, AND MULTIPLE DEVELOPMENTAL ANOMALIES.|journal=Acta Paediatrica|volume=60|issue=5|year=1971|pages=559–564|issn=0803-5253|doi=10.1111/j.1651-2227.1971.tb06990.x}}</ref><ref name="SchoonderwoerdWiesfeld2006">{{cite journal|last1=Schoonderwoerd|first1=Bas A.|last2=Wiesfeld|first2=Ans C.P.|last3=Wilde|first3=Arthur A.M.|last4=van den Heuvel|first4=Freek|last5=Van Tintelen|first5=J. Peter|last6=van den Berg|first6=Maarten P.|last7=Van Veldhuisen|first7=Dirk J.|last8=Van Gelder|first8=Isabelle C.|title=A family with Andersen-Tawil syndrome and dilated cardiomyopathy|journal=Heart Rhythm|volume=3|issue=11|year=2006|pages=1346–1350|issn=15475271|doi=10.1016/j.hrthm.2006.07.021}}</ref>


* It is understood that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
* Episodes of [[flaccid]] [[paralysis]]
* [Pathogen name] is usually transmitted via the [transmission route] route to the human host.
*[[Ventricular arrhythmias]]
* Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
*[[Dilated cardiomyopathy]]
* [Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
* Unique physical features
* The progression to [disease name] usually involves the [molecular pathway].
* The pathophysiology of [disease/malignancy] depends on the histological subtype


==References==
==References==
Line 36: Line 39:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[CME Category::Cardiology]]
[[Category:Electrophysiology]]
[[Category:Disease]]
[[Category:Genetic disorders]]
[[Category:Genetic disorders]]
[[Category: Rare disease ]]
[[Category:Cardiology]]
[[Category:Cardiology]]

Latest revision as of 14:55, 17 February 2020

Andersen-Tawil syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Andersen-Tawil syndrome from other Diseases

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Andersen-Tawil syndrome pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Andersen-Tawil syndrome pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Andersen-Tawil syndrome pathophysiology

CDC on Andersen-Tawil syndrome pathophysiology

Andersen-Tawil syndrome pathophysiology in the news

Blogs on Andersen-Tawil syndrome pathophysiology

Directions to Hospitals Treating Andersen-Tawil syndrome

Risk calculators and risk factors for Andersen-Tawil syndrome pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

It is understood that Andersen-Tawil syndrome is the result of mutation in KCNJ2 gene which encodes for Kir2.1 inward rectifier potassium channel that involves in cardiac repolarization phase. The movement of potassium ions through these channels is critical for maintaining the normal functions of skeletal muscles which are used for movement and cardiac muscle. Andersen-Tawil syndrome is a rare syndrome transmitted in autosomal dominant pattern.

Pathophysiology

Pathogenesis

Genetics

Associated Conditions

Conditions associated with Andersen-Tawil syndrome include:[12][13]

References

  1. Limberg MM, Zumhagen S, Netter MF, Coffey AJ, Grace A, Rogers J; et al. (2013). "Non dominant-negative KCNJ2 gene mutations leading to Andersen-Tawil syndrome with an isolated cardiac phenotype". Basic Res Cardiol. 108 (3): 353. doi:10.1007/s00395-013-0353-1. PMID 23644778.
  2. Doi T, Makiyama T, Morimoto T, Haruna Y, Tsuji K, Ohno S; et al. (2011). "A novel KCNJ2 nonsense mutation, S369X, impedes trafficking and causes a limited form of Andersen-Tawil syndrome". Circ Cardiovasc Genet. 4 (3): 253–60. doi:10.1161/CIRCGENETICS.110.958157. PMID 21493816.
  3. Tan SV, Z'graggen WJ, Boërio D; et al. (2012). "Membrane dysfunction in Andersen-Tawil syndrome assessed by velocity recovery cycles". Muscle Nerve. 46 (2): 193–203. doi:10.1002/mus.23293. PMID 22806368. Unknown parameter |month= ignored (help)
  4. Tristani-Firouzi M, Etheridge SP (2010). "Kir 2.1 channelopathies: the Andersen-Tawil syndrome". Pflugers Arch. 460 (2): 289–94. doi:10.1007/s00424-010-0820-6. PMID 20306271.
  5. Plaster NM, Tawil R, Tristani-Firouzi M, Canún S, Bendahhou S, Tsunoda A; et al. (2001). "Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome". Cell. 105 (4): 511–9. doi:10.1016/s0092-8674(01)00342-7. PMID 11371347.
  6. Haruna Y, Kobori A, Makiyama T, Yoshida H, Akao M, Doi T; et al. (2007). "Genotype-phenotype correlations of KCNJ2 mutations in Japanese patients with Andersen-Tawil syndrome". Hum Mutat. 28 (2): 208. doi:10.1002/humu.9483. PMID 17221872.
  7. Ballester LY, Benson DW, Wong B, Law IH, Mathews KD, Vanoye CG; et al. (2006). "Trafficking-competent and trafficking-defective KCNJ2 mutations in Andersen syndrome". Hum Mutat. 27 (4): 388. doi:10.1002/humu.9418. PMID 16541386.
  8. Tristani-Firouzi M, Jensen JL, Donaldson MR; et al. (2002). "Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome)". J. Clin. Invest. 110 (3): 381–8. PMID 12163457.
  9. Pegan S, Arrabit C, Slesinger PA, Choe S (2006). "Andersen's syndrome mutation effects on the structure and assembly of the cytoplasmic domains of Kir2.1". Biochemistry. 45 (28): 8599–606. doi:10.1021/bi060653d. PMID 16834334.
  10. Sansone V, Tawil R (2007). "Management and treatment of Andersen-Tawil syndrome (ATS)". Neurotherapeutics. 4 (2): 233–7. doi:10.1016/j.nurt.2007.01.005. PMID 17395133.
  11. Nguyen HL, Pieper GH, Wilders R (2013). "Andersen-Tawil syndrome: clinical and molecular aspects". Int J Cardiol. 170 (1): 1–16. doi:10.1016/j.ijcard.2013.10.010. PMID 24383070.
  12. Andersen, Ellen Damgaard; Krasilnikoff, Peter A.; Overvad, Hans (1971). "INTERMITTENT MUSCULAR WEAKNESS, EXTRASYSTOLES, AND MULTIPLE DEVELOPMENTAL ANOMALIES". Acta Paediatrica. 60 (5): 559–564. doi:10.1111/j.1651-2227.1971.tb06990.x. ISSN 0803-5253.
  13. Schoonderwoerd, Bas A.; Wiesfeld, Ans C.P.; Wilde, Arthur A.M.; van den Heuvel, Freek; Van Tintelen, J. Peter; van den Berg, Maarten P.; Van Veldhuisen, Dirk J.; Van Gelder, Isabelle C. (2006). "A family with Andersen-Tawil syndrome and dilated cardiomyopathy". Heart Rhythm. 3 (11): 1346–1350. doi:10.1016/j.hrthm.2006.07.021. ISSN 1547-5271.


Template:WikiDoc Sources